EA202192294A1 - Антитела к trem2 и способы их применения - Google Patents

Антитела к trem2 и способы их применения

Info

Publication number
EA202192294A1
EA202192294A1 EA202192294A EA202192294A EA202192294A1 EA 202192294 A1 EA202192294 A1 EA 202192294A1 EA 202192294 A EA202192294 A EA 202192294A EA 202192294 A EA202192294 A EA 202192294A EA 202192294 A1 EA202192294 A1 EA 202192294A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trem2
antibodies
methods
application
antibody
Prior art date
Application number
EA202192294A
Other languages
English (en)
Russian (ru)
Inventor
Марк С. Деннис
Шери Данкэн
Кэтлин Лизаинго
Кэтрин М. Монро
Джошуа И. Парк
Рейчел Пророк
Цзюй Ши
Анкита Шривастава
Беттина Ван Ленгерих
Райли Уолш
Original Assignee
Денали Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Денали Терапьютикс Инк. filed Critical Денали Терапьютикс Инк.
Publication of EA202192294A1 publication Critical patent/EA202192294A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA202192294A 2019-02-20 2020-02-20 Антитела к trem2 и способы их применения EA202192294A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962808141P 2019-02-20 2019-02-20
PCT/US2020/019093 WO2020172450A1 (en) 2019-02-20 2020-02-20 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202192294A1 true EA202192294A1 (ru) 2021-12-24

Family

ID=69844940

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192294A EA202192294A1 (ru) 2019-02-20 2020-02-20 Антитела к trem2 и способы их применения

Country Status (21)

Country Link
US (2) US12240902B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927743A1 (cg-RX-API-DMAC7.html)
JP (2) JP7543290B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210135518A (cg-RX-API-DMAC7.html)
CN (1) CN113614110B (cg-RX-API-DMAC7.html)
AR (1) AR118144A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020226754A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015656A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130086A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002206A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021012230A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192294A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21069105A (cg-RX-API-DMAC7.html)
IL (1) IL285651A (cg-RX-API-DMAC7.html)
MA (1) MA55025A (cg-RX-API-DMAC7.html)
MX (1) MX2021009722A (cg-RX-API-DMAC7.html)
PE (1) PE20211979A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552002A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108734VA (cg-RX-API-DMAC7.html)
TW (1) TWI879756B (cg-RX-API-DMAC7.html)
WO (2) WO2020172450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3902836B1 (en) * 2018-12-18 2026-03-25 Boehringer Ingelheim IO Canada Inc. Flt3 agonist antibodies and uses thereof
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021146256A1 (en) * 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
WO2022241082A1 (en) * 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
JP2026505005A (ja) 2023-01-30 2026-02-10 イーエスアーエル バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング 神経変性障害を治療するためのヒト抗trem2抗体
AU2024320793A1 (en) 2023-08-09 2026-03-12 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
KR20260113065A (ko) * 2023-11-15 2026-07-21 머크 샤프 앤드 돔 엘엘씨 인간 넥틴-4 결합제

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
RU2011133071A (ru) 2009-01-06 2013-02-20 Нестек С.А. Переработка макронутриентов
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
WO2012176779A1 (ja) * 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗erbB3抗体
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
EP3041865A2 (en) 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
EA201790342A1 (ru) * 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
JP6996979B2 (ja) * 2015-03-31 2022-02-04 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 三量体tnfファミリーリガンドを含む抗原結合分子
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
JP2019531332A (ja) 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) Trem2切断モジュレーター及びその使用
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112020001060A2 (pt) 2017-07-27 2020-07-14 Novartis Ag variantes de trem2 resistentes a shedase
HUE062436T2 (hu) * 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
WO2019032955A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019079529A1 (en) 2017-10-17 2019-04-25 The Translational Genomics Research Institute TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
BR112020013921A2 (pt) 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
WO2019246071A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
CA3109763A1 (en) 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
EP3840781A1 (en) 2018-08-22 2021-06-30 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof
SG11202102162RA (en) 2018-09-11 2021-04-29 Univ Washington Anti-trem-2 agonist antibodies
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 trem2 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
EP3894864A2 (en) 2018-12-10 2021-10-20 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
CA3120875A1 (en) 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CA3170338A1 (en) 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Also Published As

Publication number Publication date
CN113614110A (zh) 2021-11-05
SG11202108734VA (en) 2021-09-29
EP3927743A1 (en) 2021-12-29
PE20211979A1 (es) 2021-10-05
US20220073609A1 (en) 2022-03-10
JP2024164116A (ja) 2024-11-26
TWI879756B (zh) 2025-04-11
BR112021015656A2 (pt) 2021-10-05
CL2021002206A1 (es) 2022-04-22
CO2021012230A2 (es) 2021-09-30
WO2020172457A1 (en) 2020-08-27
CN113614110B (zh) 2025-03-25
PH12021552002A1 (en) 2022-09-19
WO2020172450A1 (en) 2020-08-27
TW202045543A (zh) 2020-12-16
AU2020226754A1 (en) 2021-09-16
JP7543290B2 (ja) 2024-09-02
IL285651A (en) 2021-09-30
CA3130086A1 (en) 2020-08-27
JP2022520868A (ja) 2022-04-01
US12240902B2 (en) 2025-03-04
ECSP21069105A (es) 2021-11-18
MX2021009722A (es) 2021-09-14
JP7842822B2 (ja) 2026-04-08
KR20210135518A (ko) 2021-11-15
AR118144A1 (es) 2021-09-22
MA55025A (fr) 2021-12-29
US20220119522A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
PH12022551650A1 (en) Anti-trem2 antibodies and methods of use thereof
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
MY205933A (en) Sirp-alpha binding proteins and methods of use thereof
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
EA202091339A1 (ru) Антитела против cd47 и их применение для лечения онкологических заболеваний
MY201526A (en) Anti-trem2 antibodies and methods of use thereof
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
PE20131209A1 (es) Anticuerpos anti-fap
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
MX2024011444A (es) Anticuerpos anti-npr1 y usos de los mismos.
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
JOP20240021A1 (ar) الأجسام المضادة لمستقبل إنترلوكين-4 ألفا البشري
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
PH12022550765A1 (en) Binding molecule specific for lif and use thereof
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
EA202190779A1 (ru) Антитела, стабилизирующие trem2
EA202191060A1 (ru) Анти-npr1 антитела и их применение